Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.53 |
| ▸ | JAK2 | O60674 | 9/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MUSK | O15146 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139531 | 1.00 | JAK3 (0.53) | JAK3JAK2LIMK1LIMK2NTRK1 | |
| SCHEMBL3020033 | 0.87 | JAK3 (0.57) | JAK3JAK2NTRK1MUSKLCK | |
| SCHEMBL3137061 | 0.87 | KCNH2 (0.54) | JAK3JAK2LIMK1LIMK2NTRK1 | |
| SCHEMBL3123723 | 0.87 | KCNH2 (0.42) | JAK3JAK2LIMK1LIMK2NTRK1 | |
| SCHEMBL3137082 | 0.87 | KCNH2 (0.54) | JAK3JAK2LIMK1LIMK2NTRK1 | |
| SCHEMBL3123733 | 0.87 | KCNH2 (0.42) | JAK3JAK2LIMK1LIMK2NTRK1 | |
| SCHEMBL3133640 | 0.86 | NTRK1 (0.56) | JAK3JAK2LIMK1LIMK2NTRK1 | |
| SCHEMBL3134400 | 0.86 | NTRK1 (0.58) | JAK3JAK2NTRK1 | |
| SCHEMBL3134412 | 0.86 | NTRK1 (0.58) | JAK3JAK2NTRK1 | |
| SCHEMBL3136058 | 0.82 | JAK2 (0.43) | JAK3JAK2LIMK1LIMK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853602-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-07-14 | — | — | EP | claimed |
| US-7622482-B2 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA (SE) | 2009-11-24 | — | — | US | claimed |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | claimed |
| EP-1853602-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-7622482-B2 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA (SE) | 2009-11-24 | — | — | US | disclosed |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ERBB4, ERBB2, ABL1 | JAK3 32/4885JAK2 61/4885LIMK1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.